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Dysregulated autophagy in muscle 
precursor cells from humans with 
type 2 diabetes
t. I. Henriksen  1,4, L. V. Wigge2, J. Nielsen  2, B. K. pedersen  1, M. sandri3 & C. scheele  1,4
Autophagy is active during cellular remodeling including muscle differentiation. Muscle differentiation 
is dysregulated in type 2 diabetes and we therefore hypothesize that muscle precursor cells from people 
with type 2 diabetes (T2DM) have a dysregulation of their autophagy leading to impaired myogenesis. 
Muscle precursor cells were isolated from people with T2DM or healthy controls and differentiated 
in vitro. Autophagy marker levels were assessed by immunoblotting. Differentially expressed 
autophagy-related genes between healthy and T2DM groups were identified based on a previously 
published RNA-sequencing data-set, which we verified by RT-qPCR. siRNA was used to assess the 
function of differentially expressed autophagy genes. Basal autophagy increases during human muscle 
differentiation, while T2DM muscle cells have reduced levels of autophagy marker ATG7 and show 
a blunted response to starvation. Moreover, we demonstrate that the 3 non-canonical autophagy 
genes DRAM1, VAMP8 and TP53INP1 as differentially expressed between healthy and T2DM groups 
during myoblast differentiation, and that T53INP1 knock-down alters expression of both pro-and anti-
apoptotic genes. In vitro differentiated T2DM muscle cells show differential expression of autophagy-
related genes. These genes do not regulate myogenic transcription factors but may rather be involved in 
p53-associated myoblast apoptosis during early myogenesis.
Skeletal muscle function depends on the continuous repair and maintenance of muscle fibers in a complex pro-
cess relying on satellite cells: a population of muscle precursor cells residing beneath the basal lamina, with the 
capacity to expand and progress through the myogenic program upon activation1,2. Throughout differentiation 
of these muscle precursor cells a considerable reprogramming of gene expression occurs; likewise, a substantial 
remodeling of cellular structures takes place3,4.
A candidate mechanism behind this remodeling is autophagy; a major cellular degradation pathway in which 
intracellular organelles can be broken down and recycled, thus allowing for cellular clean-up and homeostasis5. 
Adaptation to cellular stress is a key function of autophagy, and autophagy has concomitantly been shown to pro-
tect against metabolic diseases such as insulin resistance and diabetes6. Beyond its roles as a stress and starvation 
response, autophagy is also involved in cell survival, differentiation and development7,8, and importantly, recent 
murine-derived cell-based studies have shown that autophagy is required for in vitro myogenesis4,9. Moreover, it 
is becoming increasingly clear that autophagy is required for maintenance of skeletal muscle tissue. This is illus-
trated by several murine knock-out model-studies of autophagy-associated proteins showing that autophagy is 
critical for maintaining skeletal muscle mass, as well as muscle metabolism and function10–13, thus underlining the 
importance of functional autophagy in skeletal muscle.
Skeletal muscle tissue is a main target of insulin-mediated glucose uptake, and skeletal muscle insulin resist-
ance is a central step in type 2 diabetes disease progression14. Considering that autophagy is under direct regula-
tion by nutrient availability15 and the wide-ranging metabolic perturbations in T2DM, surprisingly few studies 
have investigated how type 2 diabetes affects skeletal muscle autophagy. The IGF-I/ PI3K/AKT signaling cascade 
directly inhibits skeletal muscle autophagy16, and as this pathway is dysregulated in skeletal muscle from T2DM 
individuals17, it is plausible that dysfunctional insulin signaling may lead to altered autophagy levels in skeletal 
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muscle in type 2 diabetes. While a previous study found that both basal and insulin-stimulated autophagy lev-
els were largely unaltered in skeletal muscle biopsies from patients with type 2 diabetes18, this has not yet been 
investigated in isolated muscle precursor cells during differentiation. Given the dynamic nature of autophagy it 
is possible that potential differences are blunted at tissue level, yet important at a cellular level. We have recently 
shown that differentiation is impaired in muscle precursor cells isolated from T2DM donors19. In the present 
study, our primary objective was therefore to investigate if muscle precursor cells isolated from type 2 diabetic 
donors would have altered levels of autophagy markers, suggesting altered autophagy, compared with cells from 
healthy control donors. Furthermore, we wanted to explore the role of autophagy in the T2DM-mediated dysreg-
ulated myogenesis.
Materials and Methods
Human muscle precursor cell donors. Muscle precursor cells were obtained from a subset of male 
healthy (n = 5) or type 2 diabetic (n = 5) donors (Table 1) included in a previously described study20. RNA-seq 
data was obtained from a previous study with a partial overlap in cell culture donors with the present study21. The 
WHO diagnostic criteria for type 2 diabetes were used as basis for inclusion22. All subjects gave written informed 
consent prior to commencement of study, which was performed according to the Declaration of Helsinki and 
approved by The Regional Committee on Biomedical Research Ethics in Denmark (KF 01-141/04).
Cell culture. Satellite cells were obtained from vastus lateralis muscle biopsies as previously described23. Fat 
and visible connective tissue was removed, and the muscle biopsy was minced into small pieces and digested in 
buffer containing 0.05% trypsin-EDTA, 1 mg/ml collagenase IV and 10 mg/ml BSA for 5 min at 37 °C. Digestion 
solution containing released muscle precursor cells was then transferred to cold FBS for trypsin inactivation. 
The solution was centrifuged at 800 g for 7 min. The supernatant was removed and washed with F10 nutrient 
mixture (HAM) medium. To minimize fibroblast contamination, the cell suspension was pre-plated in a culture 
plate for 3 hours in growth medium containing 20% FBS, 1% penicillin/streptomycin (PS) and 1% Fungizone 
antimycotic (FZ) in F10/HAM. The unattached muscle precursor cells were then seeded onto culture flasks coated 
with Matrigel (0.01% Matrigel in F10/HAM + supplemented with 1% PS) and cultured for 4 days in growth 
medium in a humidified incubator with 5% O2 and 5% CO2 at 37 °C. Cell culture medium was changed after 
4 days of incubation and then after every second day. At 100% confluency, cells were transferred to intermedi-
ate medium (Dulbecco’s modified Eagle’s medium (DMEM) containing 1 g/L glucose, 10% FBS and 1% PS) to 
induce alignment of muscle precursors. After 2 days, medium was changed into differentiation media (DMEM 
containing 4.5 g/L glucose, 2% horse serum (HS) and 1% PS) to induce differentiation into myotubes (myocytes). 
All cells were tested negative for mycoplasma contamination. F10/ HAM, HBSS, DMEM, FBS, HS, PS and FZ 
were obtained from Invitrogen (Taastrup, Denmark). Bafilomycin A1 was from Invivogen (Toulouse, France). 
Experiments were performed on cells at passages 5 to 6.
Healthy (n = 5) T2DM (n = 5)
Sex 5 M 5 M
Age (years) 50–59 52–66
BMI 23.8 ± 1.3 27.4 ± 0.9**
Fasting glucose 5.1 ± 0.6 9.4 ± 3.4*
OGTT 2-hour glucose 5.5 ± 0.8 17.9 ± 6.3**
Fasting insulin 42.2 ± 11 61.4 ± 17
OGTT 2-hour insulin 305.8 ± 197 223.0 ± 161
HOMA-IR 1.6 ± 0.5 4.3 ± 1.9*
VO2 max (L/min) 2.9 ± 0.7 2.43 ± 0.7
VO2 max (mL/min/kg) 35.9 ± 9.9 26.8 ± 6.4
Donors for cells used for RNA sequencing in21
Healthy (n = 6) T2DM (n = 6)
Sex 3 M/3 F 3 M/3 F
Age (years) 48–63 50–63
BMI 24.0 ± 0.6 24.4 ± 2.7
Fasting glucose 5.4 ± 0.6 9.0 ± 3.8*
OGTT 2-hour glucose 5.2 ± 1.0 18.0 ± 7.3**
Fasting insulin 25 ± 7 38 ± 35
OGTT 2-hour insulin 175 ± 123 281 ± 303
HOMA-IR 0.47 ± 0.13 0.81 ± 0.72
VO2 max (L/min) 2.4 ± 0.8 1.63 ± 0.4
VO2 max (mL/min/kg) 32.7 ± 8.8 23.2 ± 3.26
Table 1. Clinical characteristics of muscle precursor cell donors. Ages are shown as ranges; all other data are 
means ± SE. BMI, body mass index (kg/m2); OGTT, oral glucose tolerance test. Glucose values are mmol/L, 
insulin values are pmol/L. *P < 0.05, **P < 0.001, ****P < 0.0001.
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Immunomagnetic sorting of CD56+ precursor cells. To reduce the presence of non-muscle cell types 
all cell cultures were sorted using CD56-conjugated magnetic microbeads (Miltenyi Biotec, Lund, Sweden). Cells 
were grown until ~50% confluent and incubated with CD56 primary antibody conjugated microbeads, and sub-
sequently isolated by positive selection according to the manufacturer’s instructions.
siRNA transfection. Cells were transiently transfected with small interfering RNA (siRNA) oligo pools spe-
cifically targeting DRAM1, VAMP8 and TP53INP1 mRNA respectively, or a non-targeting scrambled siRNA 
pool (On-Target Plus, Dharmacon, Søborg, Denmark). Transfections were performed in >90% confluent, 
undifferentiated cells using a final concentration of 20 nM siRNA with Lipofectamine RNAimax (Invitrogen). A 
Lipofectamine-only control was included as well; all statistics for siRNA experiments were performed comparing 
the effects of siRNA with the effects of the scrambled control. The Lipofectamine control did not differ from the 
scrambled siRNA control. Transfections were performed in DMEM containing 10% FBS and no antibiotics, and 
subsequently incubated for 24 hours, at which point medium was changed to DMEM containing 10% FBS and 1% 
PS. Cells were harvested at either 48 hours (Day 0) or 7 days (Day 5) after siRNA transfection.
Immunoblot analysis. Cells were washed in ice-cold PBS and lysed using lysis buffer (20 mM Tris, 
pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 0.1% Triton X-100, protease inhibitor ((1 tablet/10 ml; 
Boehringer-Roche Diagnostics, Copenhagen, Denmark), 1% phosphatase inhibitor cocktail (Sigma-Aldrich, 
Brøndby, Denmark)). Cell lysates were centrifuged at 12000 g, 4 °C for 5 min and supernatants were collected. 
Protein concentration was determined by the Bradford reagent. 10 µg cell lysates were subjected to SDS-PAGE 
on 4–15% precast gels (Biorad), transferred to polyvinylidene difluoride (PVDF) membranes and immunoblot-
ted with primary antibodies (1:1000) as indicated in the figure legends. Primary antibodies were detected using 
species-appropriate horseradish peroxidase-conjugated secondary IgG antibody. Protein signals were visualized 
using FEMTO enhanced chemiluminescence and Biorad Chemidoc XRS imager. The signal bands were quanti-
fied using Image J software (NIH, Bethesda, MD, http://rsb.info.nih.gov/ij). Anti-ULK1, ATG7, and ATG5 anti-
bodies were from Cell Signaling (MA, US) and anti-LC3 antibody was from Nanotools (Teningen, Germany).
Immunoflourescence microscopy. In vitro differentiated human muscle stem cells were fixated 
with 4% Formaldehyde (Sigma) and then permeabilized with 0.5% Triton X-100. Cells were then incubated 
with ActinGreen 488 ReadyProbes and a nuclear counterstain was performed with Nucblue Fixed Cell stain 
ReadyProbes (Molecular probes). Fluorescence microscopy was performed with an EVOS FL (Thermo Fisher).
RNA isolation and quantitative real-time PCR. Total RNA was extracted from cells using TRIzol 
(Invitrogen, Taastrup, DK) according to manufacturer’s instructions. Total RNA was dissolved in RNase-free 
water and quantified using a Nanodrop ND 1000 (Saveen Biotech ApS, Arhus, Denmark). 0.2 µg of total RNA 
was reverse transcribed using the High Capacity Reverse Transcription kit (Applied Biosystems, Foster City, 
CA) according to manufacturer’s protocol. Real-time quantitative PCR was performed in triplicate using an 
ABI-PRISM 7900 (Applied Biosystems). Primer sequences are listed in Table 2; primer targets and genomic loca-
tions are listed in Table S1. Data analysis was performed using the comparative method (ΔΔCT).
Identification of target autophagy genes. GO-term gene members were acquired using the 
Bioconductor R package biomaRt as previously described21. All genes belonging to the GO-term Autophagy 
(GO:0006914) were cross-checked against the analysis results in21, and selected genes that were significantly 
Gene Ensembl ID Forward primer Reverse primer
B2M ENSG00000166710 GAGTATGCCTGCCGTGTGAA TTCAAACCTCCATGATGCTGC
BAD ENSG00000002330 AGACCCGGCAGACAGATGAG AGGAAGTCCCTTCTTAAAGGAGTC
BAX ENSG00000087088 ATGTTTTCTGACGGCAACTTC ATCAGTTCCGGCACCTTG
BCLX ENSG00000171552 AAAAGATCTTCCGGGGGCTG TCTGAAGGGAGAGAAAGAGATTCA
DRAM1 ENSG00000136048 GTCAACCCCTTCCTCCCGTA TCGTGGCTGCACCAAGAAAT
MYH2 ENSG00000125414 TGTCTCACTCCCAGGCTACA CCAAAAACAGCCAATTCTGAG
MYOD ENSG00000129152 CACTACAGCGGCGACTCC TAGGCGCCTTCGTAGCAG
MYOG ENSG00000122180 GCTCAGCTCCCTCAACCA GCTGTGAGAGCTGCATTCG
P21 ENSG00000124762 TCACTGTCTTGTACCCTTGTGC GGCGTTTGGAGTGGTAGA
P53 ENSG00000141510 AGGCCTTGGAACTCAAGGAT CCCTTTTTGGACTTCAGGTG
PAX7 ENSG00000009709 CGCCCATTGATGAAGACC CGGGATTCCCTTTGGAAG
PPIA ENSG00000196262 ACGCCACCGCCGAGGAAAAC TGCAAACAGCTCAAAGGAGACGC
RB1 ENSG00000139687 GGATCAGATGAAGCAGATGGA CATTCGTGTTCGAGTAGAAGTCA
TBP ENSG00000112592 GAACATCATGGATCAGAACAACAG ATAGGGATTCCGGGAGTCAT
TP53INP1 ENSG00000164938 AAATGTTTGTGGGTGAAGTCAG TGCTGAGAAACCAGTGCAAG
VAMP8 ENSG00000118640 AAGCCACATCTGAGCACTTCAA CCAGTGGCAAAGAGCACAATG
18 S ENSG00000225840 Applied Biosystems assay ID Hs99999901_s1
Table 2. Primer sequences for RT-qPCR.
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differentially expressed (adjusted p-value < 0.05) in T2DM subjects compared to healthy controls were chosen 
for further investigation.
statistical analyses. Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software 
Inc., La Jolla, CA, USA). All data within figures are presented as means ± SEM. Data in tables are presented as 
means ± SD. For comparisons between two groups, a Student’s t-test was used. For group differences and multiple 
comparisons, statistical analysis was performed using two-way ANOVA with Holm-Sidak post -hoc testing.
Results
Impairment in autophagy response in differentiated T2DM muscle cells. Considering the numer-
ous metabolic defects in T2DM muscle14, we hypothesized that T2DM myocytes would show an impaired auto-
phagy response when presented to a metabolic challenge. We therefore treated cells with HBSS medium for 
4 hours to induce starvation, followed by re-addition of insulin to the starvation medium. Re-addition of insulin 
did not result in decrease of protein abundance of Microtubule-associated protein 1A/1B-light chain 3 II (LC3II) 
levels in any of the groups and there was no over-all difference between groups in response to this treatment 
(Fig. 1A,B). The effects of insulin on LC3II in muscle tissue have previously been shown to be dependent on 
glycemic status18; the lack of autophagy response to insulin in our study might therefore be due to the relatively 
high glucose concentration in the cell culture media. Interestingly, while both healthy and T2DM groups showed 
accumulation of LC3II in response to the vacuolar H+ ATPase-inhibitor Bafilomycin A (used to assess autophagy 
flux), only the healthy group showed a significant increase in LC3II when exposed to starvation in the presence 
of Bafilomycin A (Fig. 1B), suggesting that the dynamic activation of autophagy in response to a metabolic chal-
lenge is blunted in the T2DM group. Moreover, protein levels of LC3II were also differentially regulated between 
healthy and diabetic groups with an overall decrease in the T2DM cells (Fig. 1B) indicating a lower level of auto-
phagy in this group.
Given that muscle precursor cells derived from people with T2DM have a dysregulated p53-dependent differ-
entiation19, we next aimed to determine whether the disturbed regulation of autophagy was reflected by dysreg-
ulation of autophagy-associated proteins during human myoblast differentiation. To address this question, cells 
were grown in culture and harvested at the time points indicated in Fig. 1. Immunoblot analysis of Autophagy 
related 7 and 5 (ATG7 and ATG5), unc-51 like autophagy activating kinase 1 (ULK1) and LC3II revealed a 
marked upregulation of all four proteins as cells progressed through differentiation (Fig. 1C,D). These markers 
of autophagy were chosen for analysis to ensure that proteins involved in both early and later steps of the auto-
phagic process would be assessed. At day 5, when myotubes were fully differentiated, ATG7 was markedly lower 
expressed in the cells derived from people with T2DM, whereas the rest of the assessed proteins did not differ 
between groups (Fig. 1D).
Thus, we show that basal autophagy increases during myoblast differentiation also in humans. We also found 
that muscle cells from T2DM donors have an blunted autophagy response and reduced levels of ATG7, a rate 
limiting protein of the conjugation system and therefore, of LC3 lipidation and autophagosome formation. Beside 
autophagy, ATG7 has been previously shown to be important for handling metabolic stress by targeting p53 
activity24.
DRAM1, VAMP8 and TP53INP1 are differentially expressed in T2DM muscle precursor cells. To 
further investigate the molecular dysregulations behind the reduced autophagy response to metabolic stress, we 
took on a global approach. In a previous study, we performed RNA sequencing to describe the transcriptional 
profiles of muscle cells derived from healthy or T2DM donors21. Based on these previous results, we identified sev-
eral autophagy-related genes as differentially expressed between groups (Fig. 2A). The genes Damage-Regulated 
Autophagy Modulator protein 1 (DRAM1) and Vesicle Associated Membrane Protein 8 (VAMP8) were two of 
the most up- or down-regulated genes respectively (Fig. 2A) and were therefore chosen for further analysis. The 
autophagy markers analyzed by immunoblotting in Fig. 1 were not detected as differentially expressed in the 
RNA-seq dataset when correcting for multiple testing, nor were markers of myogenesis or apoptosis. Another 
differentially expressed gene, Tumor Protein 53-inducible nuclear protein 2 (TP53INP2) was previously shown to 
regulate muscle mass and autophagy and is downregulated in muscle tissue in type 2 diabetes25. We chose to also 
include the TP53INP2 homologue Tumor Protein 53-inducible nuclear protein 1 (TP53INP1) for analysis, as it 
was previously identified as a diabetes susceptibility locus26, yet had no described role in skeletal muscle to date.
Using qPCR analysis, we verified that DRAM1, VAMP8 and TP53INP1 were indeed differentially regulated 
in T2DM cells (Fig. 2B), whereas TP53INP2 showed differential expression in proliferating cells only (Fig. S1). 
Only VAMP8 was consistently downregulated over time in the T2DM group, whereas DRAM1 was upregulated in 
fully differentiated T2DM muscle cells and TP53INP1 was downregulated in T2DM muscle precursors at day 0 of 
differentiation (Fig. 2B). Interestingly, both DRAM1 and TP53INP1 have previously been reported to positively 
regulate the capacity of p53 to control cell cycle exit and induce apoptosis27,28. p53 also plays a role in the context 
of myogenesis, since activation of the p53 target gene p21is a mandatory step for muscle precursor cells to exit the 
cell cycle and proceed through the myogenic programme29,30. Since we have previously shown that muscle precur-
sor cells from humans with type 2 diabetes have impairments in p53/p21-dependent myogenesis19, we therefore 
decided to further investigate the role of DRAM1, VAMP8 and TP53INP1 in myogenesis.
Loss of TP53INP1 results in enlarged myotubes. In accordance with previous studies4,9 we found 
that autophagy appeared to increase during muscle cell differentiation, indicating that autophagy plays a role 
in this process. We therefore hypothesized if knock down of the autophagy-associated genes DRAM1, VAMP8 
or TP53INP1 would have an impact on myogenesis. To assess this, cells were grown until confluent and siRNAs 
against DRAM1 in T2DM cells and against VAMP8 and TP53INP1 in cells from healthy donors were used to 
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Figure 1. Autophagy protein expression in myoblasts from healthy and T2DM donors. (A,B) Fully 
differentiated myotubes from healthy control or T2DM groups were starved in HBSS medium (4 hours), and 
treated with 100 nM insulin (30 minutes) and/ or Bafilomycin A1 (10 nM, 4 hours). Protein levels of LC3I/
II were measured by immunoblotting; representative blots are shown. (C) Myoblasts from healthy controls 
(n = 5) or T2DM donors (n = 5) were harvested under proliferation, at confluence (day -2), as aligned, 
undifferentiated myoblasts (day 0), at early differentiation, after 2 days in differentiation medium (day 2) and 
as fully differentiated myotubes, after 5 days in differentiation medium (day 5). Protein levels of ULK-1, ATG7, 
ATG5 and LC3I/II were measured by immunoblotting. Representative blots are shown. Two samples harvested 
from proliferating cells were not included in analysis, as protein levels were too low. A Reactive Brown stain was 
used to visualize total protein. (D) Quantifications of immunoblots shown in (c). Protein levels were normalized 
to proliferating healthy controls. Data are means ± SEM. * indicates P < 0.05; ***P < 0.001.
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knock down their respective target mRNAs. Cells were harvested 48 hours and 7 days after knockdown respec-
tively (indicated as day 0 and day 5). mRNA levels of DRAM1 (Fig. S3A) and VAMP8 and TP53INP1 (Fig. 3A,B) 
were significantly reduced after siRNA treatment and remained low throughout differentiation suggesting that 
siRNA treatment was effective. Knockdown of either DRAM1 or VAMP8 or TP53INP1 did not appear to affect 
cell viability as assessed by light microscopy at day 0 or day 5 of differentiation, since siRNA-treated cells all pro-
ceeded to form large, multinucleated myotubes during differentiation (Figs S2, S3B). However, whereas DRAM1 
and VAMP8 siRNA treatment did not affect myotube morphology, knock down of TP53INP1 lead to formation 
of visibly larger myotubes when compared to control cells (Figs 3D; S2). We next measured the mRNA expression 
of myogenic markers PAX7, MyoD, myogenin and myosin heavy chain 2 a (MYH2), to see if loss of DRAM1, 
VAMP8 or TP53INP1 would affect their expression. However, while all myogenic markers showed significant 
changes over time, we did not detect any effect of DRAM1, VAMP8 or TP53INP1 knockdown on their expression 
(Figs 3C; S2C).
Loss of TP53INP1 increases pro-and antiapoptotic markers. Growth factor withdrawal signals to 
myoblasts to exit the cell cycle and undergo differentiation; however, loss of growth factor signaling can also 
induce myoblast apoptosis31,32. TP53INP1 is a p53 target gene involved in the regulation of p53-mediated apop-
tosis27,33,34. We therefore hypothesized that loss of TP53INP1 combined with reduced presence of serum in the 
cell culture medium would alter the cells’ propensities to undergo apoptosis versus differentiate. We consequently 
Figure 2. DRAM1, VAMP8 and TP53INP1 expression in myoblast derived from humans with T2DM and 
healthy control subjects. (A) Gene counts from 21for identified differentially expressed autophagy-related 
genes (adjusted p-value < 0.5) in T2DM subjects (n = 6) versus healthy controls (n = 6). (B) Myoblasts from 
healthy controls or T2DM donors were harvested under proliferation, at confluence (day -2), as aligned, 
undifferentiated myoblasts (day 0), at early differentiation, after 2 days in differentiation medium (day 2) and as 
fully differentiated moytubes, after 5 days in differentiation medium (day 5). DRAM1, VAMP8 and TP53INP1 
mRNA was measured by RT-qPCR in healthy or T2DM muscle precursor cells. mRNA expression was 
normalized to the geometric mean of 18 s, B2M and PPIA mRNA. Data are means ± SEM. * indicates P < 0.05; 
**P < 0.01.
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measured the mRNA expression of pro-apoptotic markers BCL2-associated agonist of cell death (BAD) and 
BCL2-associated X (BAX), as well as the anti-apoptotic marker BCL2-like 1 (BCL-X) in TP53INP1 siRNA-treated 
muscle cells. Interestingly, mRNA expression of BAD was unaltered whereas BAX expression was markedly 
upregulated after knock-down of TP53INP1 with a simultaneous increase in BCL-X expression (Fig. 4A), thus 
indicating increases in both pro- and anti-apoptotic gene expression. Beyond regulating apoptosis, TP53INP1 has 
previously been reported to regulate the transcriptional activation of p53 target genes involved in myogenesis, 
including the cyclin-dependent kinase inhibitor 1 (p21)33. Interestingly, although P53 expression was not affected 
by TP53INP1 knock-down, p21 mRNA expression was robustly upregulated in TP53INP1 siRNA-treated cells, 
while the expression of RB1, another p53-induced gene required for myogenesis35,36, was unaltered (Fig. 4B). 
Hence, despite lack of change in myogenic transcription factors, our data suggest that TP53INP1 may influence 
apoptosis and cell cycle exit during early differentiation, with a visible effect on myotube size.
Figure 3. Effect of VAMP8 and TP53INP1 knock down on myogenic marker expression. Myoblasts from 
healthy controls (n = 5) were treated with 20 nM siRNA oligonucleotides targeting VAMP8 or TP53INP1, 
or with a non-targeting scrambled control. A lipofectamine-only control was included for each experiment 
(data not shown) to confirm no off-target effects of the scrambled siRNA control. Cells at >90% confluence 
were treated with siRNA and harvested 48 hours or 7 days after siRNA treatment; indicated as day 0 or day 5 
respectively. (A,B) VAMP8 and TP53INP1 mRNA levels were measured by RT-qPCR and normalized to TBP 
mRNA. The same control was used for both knock-downs. (C) Light microscopy images of siRNA-treated 
cells at 4X magnification; scale bar indicates 1000 µM. (D) Expression of myogenic markers PAX7, MYOD, 
MYOG and MYH2 in healthy control myoblasts treated with VAMP8, TP53INP1 or control siRNA. Data are 
means ± SEM. * indicates P < 0.05; **P < 0.01, ***P < 0.001.
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Discussion
In the present study we demonstrated reduced autophagy response to metabolic stress in human muscle precur-
sor cells from humans with T2DM. Upon in vitro differentiation, these cells had lower protein levels of ATG7, 
up-regulated mRNA levels of DRAM1 and down-regulated mRNA levels of VAMP8. In addition, TP53INP1 was 
downregulated in the early differentiation state. Through a loss-of-function approach we demonstrated that this 
downregulation results in an increase in the apoptosis genes BAX and BCL-X and the cell cycle regulator p21 at 
early differentiation, and enlarged myotubes once the cells are fully differentiated. Our data thus provide novel 
insight into the mechanisms manifested in muscle precursor cells in T2DM and highlight that a dysregulation of 
autophagy genes may contribute to the muscular phenotype of T2DM in humans.
The study was limited to in vitro experiments and thus only reflects the dysregulations in autophagy that 
are manifested in the muscle precursor cells even after in vitro expansion. However, an advantage is that we 
have utilized isolated cells from multiple human donors, thus including a biological variation from individuals 
that are suffering from T2DM. Moreover, using a cell-based approach allows us to study autophagy flux, which 
importantly cannot be done in muscle biopsies. In line with this, attempts to assess whether baseline autophagy is 
dysregulated in skeletal muscle biopsies in type 2 diabetes patients have resulted in conflicting findings, reporting 
either down-regulation37 or no difference from healthy controls18. These results might reflect the difficulties of 
measuring a dynamic mechanism such as autophagy in a biopsy including several cell types as well as muscle cells 
in different stages from precursor cell to differentiated myotube.
An increase in basal autophagy during C2C12 myogenesis has been previously demonstrated in several stud-
ies4,9,38; the current study provides the first evidence that this also occurs during human myogenesis. We pre-
viously showed that myogenesis is impaired in T2DM muscle cells, and that this dysregulation was associated 
with impaired signaling of p53 and the p53 target gene p2119. The current study support this concept of altered 
p53 signaling in T2DM muscle cells by demonstrating that two direct transcriptional targets of p53 (DRAM1 
and TP53INP1)27,39 are dysregulated in T2DM cells. While we expected to detect a difference in basal autophagy 
between cells from healthy and T2DM donors, we only found a difference in expression of ATG7, although 
this was not reproducible in our global gene expression analysis. ATG7 is a critical regulator of autophagy40; 
however, further studies are required to explore the potential dysregulation of autophagy in T2DM muscle cells. 
Nevertheless, as ATG7 has previously been shown to regulate the response to metabolic stress through interaction 
with p53 and subsequent induction of p21 transcription24, our finding that ATG7 is downregulated in T2DM 
muscle cells further supports the notion of altered p53 signaling in T2DM muscle cells.
Figure 4. Effect of TP53INP1 knock down on P53 and apoptosis-related gene expression. Myoblasts from 
healthy controls (n = 5) were treated with 20 nM siRNA oligonucleotides targeting TP53INP1, or with a non-
targeting scrambled control. A lipofectamine-only control was included (data not shown) to confirm no off-
target effects of the scrambled siRNA control. Cells at >90% confluence were treated with siRNA, and harvested 
48 hours or 7 days after siRNA treatment. (A) mRNA expression of pro-apoptotic markers BAD and BAX or 
anti-apoptotic marker BCL-X. (B) mRNA expression of P53, MDM2, RB1 and p21 in healthy control myoblasts 
treated with TP53INP1 or control siRNA. (B) Data are means ± SEM. * indicates P < 0.05; **P < 0.01, 
***P < 0.001.
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Genome-wide association studies have identified TP53INP1 as a diabetes susceptibility locus26,41 and interest-
ingly, tp53inp1-deficient mice have chronic oxidative stress accompanied by insulin resistance and an increased 
number of dysfunctional mitochondria due to PINK1/ PARKIN-mediated impaired mitophagy42. We found that 
TP53INP1 was downregulated in early differentiation, when cells were confluent but not yet fused. Muscle pre-
cursor cells committed to differentiation are prone to undergo apoptosis43 and TP53INP1 can promote apoptosis 
in an autophagy-dependent manner34. Paradoxically, we found that TP53INP1 knockdown increased mRNA 
expression of both pro-and-antiapoptotic genes, while also increasing p21 expression. This may be explained 
by previous studies showing that although TP53INP1 promotes apoptosis, TP53INP1 deficiency leads to ROS 
accumulation and consequentially upregulation of p21 and BAX expression44. In turn, p21 conveys anti-apoptotic 
effects to differentiating muscle cells31 and promotes BCL-X expression45,46; thus the observed increased expres-
sion of BCL-X after TP53INP1 knock-down might reflect a compensatory p21-mediated anti-apoptotic response. 
Given that p21 is involved in cell cycle exit during early differentiation, this up-regulation might also explain our 
observation of enlarged myotubes following TP53INP1 knockdown. Thus, despite the lack of alterations in the 
measured myogenic markers, we propose that the downregulation of TP53INP1 in muscle precursor cells from 
people with T2DM might affect the early state of myogenesis leading to an imbalance between apoptosis and cell 
cycle exit, which may disturb proper differentiation. Nevertheless, our studies were limited to mRNA expression 
analysis; the use of more functional apoptosis assays would be necessary to explore the role of TP53INP1 in 
myogenesis-associated apoptosis. In line with this, further mechanistic studies examining exactly how TP53INP1 
interacts with the autophagic machinery, such as co-localization experiments would be required to elucidate the 
specific roles of TP53INP1 in autophagy regulation.
Although we identified both VAMP8 and DRAM1 to be dysregulated in muscle cells derived from humans 
with T2DM, we were unable to further pinpoint their function in the current cell model. VAMP8 is a soluble 
N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) involved in autophagosome-lysosome 
fusion47, which has also been described in adipocyte GLUT4 trafficking48–50. Interestingly, Vamp8 knock-out mice 
have markedly increased insulin sensitivity and muscle glucose uptake51, suggesting that the downregulation in 
human muscle cells from people with T2DM, might be a compensatory action to ameliorate impaired insulin 
action. This idea however remains to be explored. DRAM1 is required for p53-regulated autophagy and is upreg-
ulated in response to genotoxic stress28. The fact that we found DRAM1 to be upregulated in fully differentiated 
T2DM myotubes may thus be a consequence of cellular stress in the T2DM cells, and it may explain why loss of 
DRAM1 in undifferentiated muscle cells had no effect on myogenic progression.
Conclusion
Our data suggest that muscle precursor cells from humans with T2DM have an altered expression of autophagy 
markers during metabolic stress and we identify a gene expression profile of autophagy-associated genes which 
are dysregulated in these cells. One of these genes, TP53INP1, seems to act in early myogenesis to regulate the 
balance between apoptosis and cell cycle exit and might thus be important in vivo to mediate proper muscle 
differentiation.
Data Availability
The data that support the findings of this study are available from the corresponding authors upon reasonable 
request.
References
 1. Le Grand, F. & Rudnicki, M. A. Skeletal muscle satellite cells and adult myogenesis. Current Opinion in Cell Biology 19, 628–633 
(2007).
 2. Mauro, A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 9, 493–5 (1961).
 3. Wagers, A. J. & Conboy, I. M. Cellular and Molecular Signatures of Muscle Regeneration: Current Concepts and Controversies in 
Adult Myogenesis. Cell 122, 659–667 (2005).
 4. Sin, J. et al. Mitophagy is required for mitochondrial biogenesis and myogenic differentiation of C2C12 myoblasts. Autophagy 12, 
369–380 (2016).
 5. Mizushima, N. & Komatsu, M. Autophagy: Renovation of Cells and Tissues. Cell 147, 728–741 (2011).
 6. Yang, L., Li, P., Fu, S., Calay, E. S. & Hotamisligil, G. S. Defective hepatic autophagy in obesity promotes ER stress and causes insulin 
resistance. Cell Metab. 11, 467–78 (2010).
 7. Levine, B. & Kroemer, G. Autophagy in the Pathogenesis of Disease., https://doi.org/10.1016/j.cell.2007.12.018.
 8. Salemi, S., Yousefi, S., Constantinescu, M. A., Fey, M. F. & Simon, H.-U. Autophagy is required for self-renewal and differentiation 
of adult human stem cells. Cell Res. 22, 432–5 (2012).
 9. Fortini, P. et al. The fine tuning of metabolism, autophagy and differentiation during in vitro myogenesis. Cell Death Dis. 7, e2168 
(2016).
 10. Masiero, E. et al. Autophagy is required to maintain muscle mass. Cell Metab. 10, 507–15 (2009).
 11. De Palma, C. et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis. 3, e418 (2012).
 12. He, C. et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 481, 511–5 (2012).
 13. Kim, K. H. et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. 
Med. 19, 83–92 (2012).
 14. Phielix, E. & Mensink, M. Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol. Behav. 94, 252–8 (2008).
 15. Mizushima, N., Yamamoto, A., Matsui, M., Yoshimori, T. & Ohsumi, Y. In vivo analysis of autophagy in response to nutrient 
starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell 15, 1101–11 (2004).
 16. Zhao, J. et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in 
atrophying muscle cells. Cell Metab. 6, 472–83 (2007).
 17. Krook, A., Roth, R. A., Jiang, X. J., Zierath, J. R. & Wallberg-Henriksson, H. Insulin-Stimulated Akt Kinase Activity Is Reduced in 
Skeletal Muscle From NIDDM Subjects. Diabetes 47, 1281–1286 (1998).
 18. Kruse, R., Vind, B. F., Petersson, S. J., Kristensen, J. M. & Højlund, K. Markers of autophagy are adapted to hyperglycaemia in skeletal 
muscle in type 2 diabetes. Diabetologia 58, 2087–2095 (2015).
 19. Henriksen, T. I. et al. Dysregulation of a novel miR-23b/27b-p53 axis impairs muscle stem cell differentiation of humans with type 
2 diabetes. Mol. Metab., https://doi.org/10.1016/j.molmet.2017.04.006 (2017).
1 0Scientific RepoRts |          (2019) 9:8169  | https://doi.org/10.1038/s41598-019-44535-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
 20. Pedersen, M. et al. Cognitive functions in middle aged individuals are related to metabolic disturbances and aerobic capacity: a 
cross-sectional study. PLoS One 7, e51132 (2012).
 21. Väremo, L. et al. Type 2 diabetes and obesity induce similar transcriptional reprogramming in human myocytes. Genome Med. 9, 47 
(2017).
 22. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. World Heal. Organ (2006).
 23. Green, C. J., Pedersen, M., Pedersen, B. K. & Scheele, C. Elevated NF-κB Activation Is Conserved in Human Myocytes Cultured 
From Obese Type 2 Diabetic Patients and Attenuated by AMP-Activated Protein Kinase. Diabetes 60, 2810–2819 (2011).
 24. Lee, I. H. et al. Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science 336, 225–8 (2012).
 25. Sala, D. et al. Autophagy-regulating TP53INP2 mediates muscle wasting and is repressed in diabetes. J. Clin. Invest. 124, 1914–1927 
(2014).
 26. Voight, B. F. et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42, 
579–589 (2010).
 27. Okamura, S. et al. p53DINP1, a p53-Inducible Gene, Regulates p53-Dependent Apoptosis. Mol. Cell 8, 85–94 (2001).
 28. Crighton, D. et al. DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis. Cell 126, 121–134 (2006).
 29. Hawke, T. J. et al. p21 is essential for normal myogenic progenitor cell function in regenerating skeletal muscle. Am. J. Physiol. Cell 
Physiol. 285, C1019–27 (2003).
 30. Guo, K., Wang, J., Andrés, V., Smith, R. C. & Walsh, K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity 
upon myocyte terminal differentiation. Mol. Cell. Biol. 15, 3823–9 (1995).
 31. Wang, J. & Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273, 359–61 
(1996).
 32. McClearn, D., Medville, R. & Noden, D. Muscle cell death during the development of head and neck muscles in the chick embryo. 
Dev. Dyn. 202, 365–377 (1995).
 33. Tomasini, R. et al. TP53INP1s and Homeodomain-interacting Protein Kinase-2 (HIPK2) Are Partners in Regulating p53 Activity. J. 
Biol. Chem. 278, 37722–37729 (2003).
 34. Seillier, M. et al. TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region 
(LIR) and promotes autophagy-dependent cell death. Cell Death Differ. 19, 1525–35 (2012).
 35. Porrello, A. et al. p53 regulates myogenesis by triggering the differentiation activity of pRb. J. Cell Biol. 151, 1295–304 (2000).
 36. Wang, J., Guo, K., Wills, K. N. & Walsh, K. Rb functions to inhibit apoptosis during myocyte differentiation. Cancer Res. 57, 351–4 
(1997).
 37. Møller, A. B. et al. Altered gene expression and repressed markers of autophagy in skeletal muscle of insulin resistant patients with 
type 2 diabetes. Sci. Rep. 7, 43775 (2017).
 38. McMillan, E. M. & Quadrilatero, J. Autophagy is required and protects against apoptosis during myoblast differentiation. Biochem. 
J. 462, 267–277 (2014).
 39. Xie, X., Le, L., Fan, Y., Lv, L. & Zhang, J. Autophagy is induced through the ROS-TP53-DRAM1 pathway in response to 
mitochondrial protein synthesis inhibition. Autophagy 8, 1071–1084 (2012).
 40. Komatsu, M. et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J. Cell Biol. 169 (2005).
 41. Cauchi, S. et al. European genetic variants associated with type 2 diabetes in North African Arabs. Diabetes Metab. 38, 316–323 
(2012).
 42. Seillier, M. et al. Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1. EMBO Mol. Med. 7, 
802–18 (2015).
 43. Sandri, M. & Carraro, U. Apoptosis of skeletal muscles during development and disease. Int. J. Biochem. Cell Biol. 31, 1373–1390 
(1999).
 44. Cano, C. E. et al. Tumor Protein 53–Induced Nuclear Protein 1 Is a Major Mediator of p53 Antioxidant Function. Cancer Res. 69 
(2008).
 45. Wu, Y.-C. M. & O’Reilly, M. A. Bcl-XL is the primary mediator of p21 protection against hyperoxia-induced cell death. Exp. Lung Res. 
37, 82–91 (2011).
 46. Staversky, R. J. et al. p21Cip1/Waf1/Sdi1 protects against hyperoxia by maintaining expression of Bcl-XL. Free Radic. Biol. Med. 41, 
601–609 (2006).
 47. Itakura, E., Kishi-Itakura, C. & Mizushima, N. The Hairpin-type Tail-Anchored SNARE Syntaxin 17 Targets to Autophagosomes for 
Fusion with Endosomes/Lysosomes. Cell 151, 1256–1269 (2012).
 48. Zhao, P. et al. Variations in the requirement for v-SNAREs in GLUT4 trafficking in adipocytes. J. Cell Sci. 122, 3472–3480 (2009).
 49. Williams, D. & Pessin, J. E. Mapping of R-SNARE function at distinct intracellular GLUT4 trafficking steps in adipocytes. J. Cell Biol. 
180, 375–387 (2008).
 50. Sadler, J. B. A., Bryant, N. J. & Gould, G. W. Characterization of VAMP isoforms in 3T3-L1 adipocytes: implications for GLUT4 
trafficking. Mol. Biol. Cell 26, 530–536 (2015).
 51. Zong, H. et al. Enhanced energy expenditure, glucose utilization, and insulin sensitivity in VAMP8 null mice. Diabetes 60, 30–8 
(2011).
Acknowledgements
Sarah Heywood and Ricardo Soares from The Centre for Physical Activity Research (CFAS) are acknowledged for 
their technical assistance. CFAS is supported by a grant from TrygFonden. This study was supported by a grant 
from the Novo Nordisk Foundation (C.S.), by a PhD scholarship from Faculty of Health Sciences, University 
of Copenhagen (T.I.H.) and by funding from the Knut and Alice Wallenberg Foundation (J.N. and L.V.W). 
The Centre for Physical Activity Research (CFAS) is supported by a grant from Trygfonden. The Novo Nordisk 
Foundation Center for Basic Metabolic Research (http://www.metabol.ku.dk) is supported by an unconditional 
grant from the Novo Nordisk Foundation to University of Copenhagen.
Author Contributions
T.I.H. and C.S. designed the study; C.S. directed the study; T.I.H. and L.V.W. collected and analyzed data; T.I.H. 
drafted the manuscript; T.I.H., L.V.W., J.N., B.K.P., S.M. and C.S. interpreted data and edited and approved the 
final version of the article.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44535-2.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
1 1Scientific RepoRts |          (2019) 9:8169  | https://doi.org/10.1038/s41598-019-44535-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
